DE69838002D1 - Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten - Google Patents

Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten

Info

Publication number
DE69838002D1
DE69838002D1 DE69838002T DE69838002T DE69838002D1 DE 69838002 D1 DE69838002 D1 DE 69838002D1 DE 69838002 T DE69838002 T DE 69838002T DE 69838002 T DE69838002 T DE 69838002T DE 69838002 D1 DE69838002 D1 DE 69838002D1
Authority
DE
Germany
Prior art keywords
cell proliferation
phenyl
substituted
treating
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838002T
Other languages
English (en)
Other versions
DE69838002T2 (de
Inventor
Carlo Brugnara
Jose Halperin
Rudolf Fluckiger
Emile M Bellott
Richard John Lombardy
John J Clifford
Ying-Duo Gao
Reem M Haidar
Eugene W Kelleher
Adel M Moussa
Yesh P Sachdeva
Minghua Sun
Heather N Taft
Michael H Zeldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Childrens Medical Center Corp
Original Assignee
Harvard College
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Childrens Medical Center Corp filed Critical Harvard College
Publication of DE69838002D1 publication Critical patent/DE69838002D1/de
Application granted granted Critical
Publication of DE69838002T2 publication Critical patent/DE69838002T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE69838002T 1997-11-20 1998-11-20 Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten Expired - Lifetime DE69838002T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97559297A 1997-11-20 1997-11-20
US975592 1997-11-20
PCT/US1998/024787 WO1999026929A1 (en) 1997-11-20 1998-11-20 Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

Publications (2)

Publication Number Publication Date
DE69838002D1 true DE69838002D1 (de) 2007-08-09
DE69838002T2 DE69838002T2 (de) 2008-03-06

Family

ID=25523175

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838002T Expired - Lifetime DE69838002T2 (de) 1997-11-20 1998-11-20 Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten

Country Status (14)

Country Link
US (2) US6534497B1 (de)
EP (1) EP1047676B1 (de)
JP (1) JP3790425B2 (de)
CN (1) CN1119334C (de)
AT (1) ATE365718T1 (de)
AU (1) AU749960B2 (de)
BR (1) BR9815617A (de)
CA (1) CA2310748C (de)
DE (1) DE69838002T2 (de)
ES (1) ES2293699T3 (de)
IL (2) IL136225A0 (de)
MX (1) MXPA00005035A (de)
NZ (1) NZ505280A (de)
WO (1) WO1999026929A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
US6992079B2 (en) * 1997-11-20 2006-01-31 President Fellows of Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US20120270238A1 (en) * 2009-10-22 2012-10-25 Moro Ricardo J Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof
FR3024778B1 (fr) * 2014-08-05 2021-01-22 Screencell Procede pour le depistage de la drepanocytose et kit pour sa mise en oeuvre

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546165A (en) 1966-02-01 1970-12-08 Du Pont Soluble high-melting,thermally stable linear polyesters
US4006023A (en) 1974-10-07 1977-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare Photographic polymeric composition containing a leuco dye cyanide
US4806685A (en) 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
EP0323740A3 (de) 1987-12-24 1990-12-12 California Biotechnology, Inc. Lineare Analoge von atrialen natriuretischen Peptiden
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
US5358959A (en) 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
WO1996008242A2 (en) 1994-09-16 1996-03-21 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease
JP4099226B2 (ja) 1994-09-16 2008-06-11 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 哺乳類細胞の増殖を治療するためのハロゲン化芳香族の使用
AU5864796A (en) 1995-05-19 1996-11-29 Sphere Biosystems, Inc. Multiply-substituted fullerenes and methods for their prepar ation and characterization
US6063921A (en) * 1997-11-20 2000-05-16 Pharm-Eco Laboratories, Inc. Synthesis of 11-aryl-5,6-dihydro-11H-dibenz[b,e]azepines
US6291449B1 (en) * 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours

Also Published As

Publication number Publication date
IL136225A0 (en) 2001-05-20
EP1047676B1 (de) 2007-06-27
AU1797399A (en) 1999-06-15
WO1999026929A1 (en) 1999-06-03
US6534497B1 (en) 2003-03-18
IL136225A (en) 2007-10-31
MXPA00005035A (es) 2002-10-11
US20030191111A1 (en) 2003-10-09
CN1299350A (zh) 2001-06-13
DE69838002T2 (de) 2008-03-06
CA2310748A1 (en) 1999-06-03
ES2293699T3 (es) 2008-03-16
JP3790425B2 (ja) 2006-06-28
NZ505280A (en) 2003-01-31
BR9815617A (pt) 2001-10-16
AU749960B2 (en) 2002-07-04
JP2001524470A (ja) 2001-12-04
CA2310748C (en) 2008-07-22
EP1047676A4 (de) 2001-11-14
ATE365718T1 (de) 2007-07-15
CN1119334C (zh) 2003-08-27
EP1047676A1 (de) 2000-11-02

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE443044T1 (de) Tace inhibitoren
DE69838002D1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE69821652D1 (de) Substituierte diphenylindanone, -indane und -indolverbindungen und deren analogue zur verwendung in der prophylaxe und behandlung von krankheiten die sich durch anormale zellproliferation auszeichnen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE358495T1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition